Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Retreatment in Myelofibrosis
NCT02091752Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myelofibrosis (MF), sponsored by Novartis. Primary endpoint: Proportion of Patients Achieving ≥20% Reduction From Baseline in Spleen Volume at 24 weeks. Started Sep 2014; status: terminated.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02091752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091752.